// App-Quantinova.ai

27 : Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.

Researchers

Presenter

  • Nobuaki Matsubara

Principal Investigators

  • David Olmos

  • Giuseppe Procopio

  • Satoru Kawakami

  • Yuksel Urun

  • Robbert J. van Alphen

  • Aude Flechon

  • Michael Anthony Carducci

  • Young Deuk Choi

  • Sebastien J. Hotte

  • Ernesto Pablo Korbenfeld

  • Gero Kramer

  • Neeraj Agarwal

  • Simon Dearden

  • Christopher Gresty

  • Jinyu Kang

  • Christian Heinrich Poehlein

  • Elizabeth Harrington

  • Maha H. A. Hussain

Medical Centers

  • National Cancer Center Hospital, Tokyo, Japan

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Spanish National Cancer Research Centre (CNIO), Madrid and Hospitales Universitarios Virgen de la Victoria y Regional, Institute of Biomedical Research in Malaga, Malaga, Spain

  • Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy

  • Department of Pulumonary Medicine, Saitama Medical Center, Saitama Medical University, Saitama, Japan

  • Department of Pediatrics, Ankara University, Ankara, Turkey

  • Department of Obstetrics and Gynecology, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands

  • Cancérologie Médicale, Centre Léon-Bérard, Lyon Cedex, France

  • Johns Hopkins Kimmel Cancer Center, Baltimore, MD

  • Department of Cardiology, Yonsei University Severance Hospital, Seoul, South Korea

  • Juravinski Cancer Centre, Burlington, ON, Canada

  • Hospital Aleman de Buenos Aires, Buenos Aires, Argentina

  • AKH Wien, Wien, Austria

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • AstraZeneca, Precision Medicine and Biosamples, Cambridge, United Kingdom

  • AstraZeneca, Gaithersburg, MD

  • Merck & Co., Inc., Kenilworth, NJ

  • Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom

  • Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

Locations

  • Japan

  • United Kingdom

  • Spain

  • Italy

  • Turkey

  • Netherlands

  • France

  • United States

  • Republic of South Korea

  • Canada

  • Argentina

  • Austria

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • BRCA mutation

  • Circulating DNA

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Cohort

Phase

  • III

Study Id's

  • NCT02987543

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved